This site became the new ClinicalTrials.gov on June 19th. Learn more.
Show more
ClinicalTrials.gov Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu
Give us feedback

Durvalumab and Tremelimumab in Combination With First-Line Chemotherapy in Advanced Solid Tumors

This study is currently recruiting participants.
See Contacts and Locations
Verified July 2017 by AstraZeneca
Sponsor:
Information provided by (Responsible Party):
AstraZeneca
ClinicalTrials.gov Identifier:
NCT02658214
First received: January 11, 2016
Last updated: July 5, 2017
Last verified: July 2017
  Purpose
Durvalumab and Tremelimumab in combination with first-line chemotherapy in the following indications: Ovarian/peritoneal/fallopian tube cancer, SCCHN, TNBC, SCLC and gastric/GEJ cancer.

Condition Intervention Phase
Small Cell Lung Carcinoma Carcinoma, Squamous Cell of Head and Neck Stomach Neoplasms Triple Negative Breast Neoplasms Ovarian Neoplasms Fallopian Tube Neoplasms Peritoneal Neoplasms Esophagogastric Junction Neoplasms Drug: paclitaxel + carboplatin Drug: carboplatin + etoposide Drug: gemcitabine + carboplatin Drug: nab-paclitaxel (paclitaxel-albumin) + carboplatin Drug: oxaliplatin + 5-fluorouracil (5FU) + leucovorin (calcium folinate/folinic acid) Biological: durvalumab Biological: tremelimumab Phase 1

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase Ib Study to Evaluate the Safety and Tolerability of Durvalumab and Tremelimumab in Combination With First-Line Chemotherapy in Patients With Advanced Solid Tumors.

Resource links provided by NLM:


Further study details as provided by AstraZeneca:

Primary Outcome Measures:
  • Laboratory findings (including: clinical chemistry, hematology, and urinalysis) [ Time Frame: Throughout the study, approximately two years ]
    To assess the safety and tolerability profile of first-line chemotherapy in combination with durvalumab + tremelimumab

  • Incidence of Adverse Events [ Time Frame: Throughout the study, approximately two years ]
    To assess incidence of Adverse Events for the safety and tolerability profile of first-line chemotherapy in combination with durvalumab and tremelimumab


Estimated Enrollment: 60
Actual Study Start Date: April 28, 2016
Estimated Study Completion Date: July 1, 2019
Estimated Primary Completion Date: July 1, 2019 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Cohort 1
ovarian/peritoneal/fallopian tube cancer and squamous cell carcinoma of the head and neck (SCCHN)
Drug: paclitaxel + carboplatin
IV infusion
Biological: durvalumab
IV infusion
Other Name: Medi-4736
Biological: tremelimumab
IV infusion
Experimental: Cohort 2
Small-cell lung cancer (SCLC)
Drug: carboplatin + etoposide
IV infusion
Biological: durvalumab
IV infusion
Other Name: Medi-4736
Biological: tremelimumab
IV infusion
Experimental: Cohort 3
Triple-negative breast cancer (TNBC)
Drug: gemcitabine + carboplatin
IV infusion
Biological: durvalumab
IV infusion
Other Name: Medi-4736
Biological: tremelimumab
IV infusion
Experimental: Cohort 4
Triple-negative breast cancer (TNBC)
Drug: nab-paclitaxel (paclitaxel-albumin) + carboplatin
IV infusion
Biological: durvalumab
IV infusion
Other Name: Medi-4736
Biological: tremelimumab
IV infusion
Experimental: Cohort 5
Gastric/gastro-esophageal junction (GEJ)
Drug: oxaliplatin + 5-fluorouracil (5FU) + leucovorin (calcium folinate/folinic acid)
IV infusion and bolus administration
Biological: durvalumab
IV infusion
Other Name: Medi-4736
Biological: tremelimumab
IV infusion

Detailed Description:

The study will screen approximately 100 patients in order to have a total of approximately 80 evaluable patients in 5 cohorts of first-line chemotherapy regimens combined with durvalumab + tremelimumab.

This study will evaluate the safety and tolerability of durvalumab (MEDI4736) + tremelimumab in combination with first line chemotherapy regimens in patients with locally advanced or metastatic solid tumors: ovarian/peritoneal/fallopian tube cancer, squamous cell carcinoma of the head and neck (SCCHN), triple negative breast cancer (TNBC), small cell lung carcinoma (SCLC), and gastric/gastro-esophageal junction (GEJ) cancer.

  Eligibility

Ages Eligible for Study:   18 Years to 99 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

1. Age ≥18 years at the time of screening 2. Written informed consent and any locally required authorization 4. Patients with histologically or cytologically documented chemotherapy-naive locally advanced unresectable or metastatic ovarian/peritoneal/fallopian tube cancer, SCCHN, TNBC, SCLC, and gastric cancer/GEJ.

4a. SCCHN patients who are candidates for definitive chemoradiation are not eligible to participate.

4b. Gastric/GEJ cancer is defined as HER-2 negative adenocarcinoma (not eligible for anti-HER-2 therapy).

5. ECOG performance status of 0 or 1 6. At least 1 lesion, not previously irradiated, that can be accurately measured at baseline 7. No prior exposure to immune-mediated therapy 8. Adequate organ and marrow function

Exclusion Criteria:

  1. Receipt of any investigational anticancer therapy within 28 days or 5 half-lives, whichever is longer, prior to the first dose of study treatment
  2. Brain metastases or spinal cord compression unless asymptomatic or treated and stable off steroids and anti-convulsants for at least 1 month prior to study treatment
  3. Any unresolved Grade ≥2 toxicity from previous anticancer therapy
  4. Active or prior documented autoimmune or inflammatory disorders
  5. Uncontrolled intercurrent illness, including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, uncontrolled hypertension, unstable angina pectoris, cardiac arrhythmia, interstitial lung disease, or psychiatric illness/social situations that would limit compliance with study requirement, substantially increase risk of incurring AEs from study drugs, or compromise the ability of the patient to give written informed consent
  6. Mean QT interval corrected for heart rate using Fridericia's formula (QTcF) ≥470 ms 20. Active tuberculosis
  7. Active infection including hepatitis B, hepatitis C, or human immunodeficiency virus (HIV)
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT02658214

Contacts
Contact: AstraZeneca Clinical Study Information Center 1-877-240-9479 information.center@astrazeneca.com
Contact: AstraZeneca Cancer Study Locator Service 1-877-400-4656 AstraZeneca@emergingmed.com

Locations
United States, Georgia
Research Site Withdrawn
Augusta, Georgia, United States, 30912
United States, Pennsylvania
Research Site Withdrawn
Pittsburgh, Pennsylvania, United States, 15232
Korea, Republic of
Research Site Recruiting
Seoul, Korea, Republic of, 03080
Research Site Recruiting
Seoul, Korea, Republic of, 03722
Research Site Recruiting
Seoul, Korea, Republic of, 05505
Research Site Recruiting
Seoul, Korea, Republic of, 06351
Sponsors and Collaborators
AstraZeneca
  More Information

Responsible Party: AstraZeneca
ClinicalTrials.gov Identifier: NCT02658214     History of Changes
Other Study ID Numbers: D419SC00001
Study First Received: January 11, 2016
Last Updated: July 5, 2017

Keywords provided by AstraZeneca:
durvalumab, MEDI4736, tremelimumab, small-cell lung, head and neck, triple negative breast, gastric/GEJ or ovarian cancer, immuno oncology, first-line chemo

Additional relevant MeSH terms:
Carcinoma
Neoplasms
Breast Neoplasms
Lung Neoplasms
Ovarian Neoplasms
Stomach Neoplasms
Carcinoma, Squamous Cell
Small Cell Lung Carcinoma
Peritoneal Neoplasms
Fallopian Tube Neoplasms
Head and Neck Neoplasms
Triple Negative Breast Neoplasms
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Neoplasms by Site
Breast Diseases
Skin Diseases
Respiratory Tract Neoplasms
Thoracic Neoplasms
Lung Diseases
Respiratory Tract Diseases
Endocrine Gland Neoplasms
Ovarian Diseases
Adnexal Diseases
Genital Diseases, Female
Genital Neoplasms, Female
Urogenital Neoplasms
Endocrine System Diseases
Gonadal Disorders
Gastrointestinal Neoplasms

ClinicalTrials.gov processed this record on September 21, 2017